Synthetic Biologics, Inc., a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients. Its lead product candidates are in Phase III development, such as SYN-004 that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection, overgrowth of pathogenic organisms, and the emergence of antimicrobial resistance; and SYN-010 which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The company's preclinical products include an oral formulation of the enzyme intestinal alkaline phosphatase to treat local GI disorders and systemic diseases; monoclonal antibody therapies for the prevention and treatment of pertussis; and novel discovery stage biotherapeutics for the treatment of phenylketonuria. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. The company was formerly known as Adeona Pharmaceuticals, Inc. and changed its name to Synthetic Biologics, Inc. in February 2012. Synthetic Biologics, Inc. was founded in 2001 and is headquartered in Rockville, Maryland.
Industry, Sector and Symbol
Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:SYN
CUSIPN/A
Phone+1-734-3327800
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on Assets53.56%
Miscellaneous
EmployeesN/A
Outstanding Shares3,800,000
Market Cap$49.23 million
Synthetic Biologics (NYSEAMERICAN:SYN) Frequently Asked Questions
What is Synthetic Biologics' stock symbol?
Synthetic Biologics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "SYN."
When did Synthetic Biologics' stock split? How did Synthetic Biologics' stock split work?
Synthetic Biologics shares reverse split on the morning of Monday, August 13th 2018. The 1-35 reverse split was announced on Wednesday, August 1st 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 10th 2018. An investor that had 100 shares of Synthetic Biologics stock prior to the reverse split would have 3 shares after the split.
How were Synthetic Biologics' earnings last quarter?
Synthetic Biologics Inc (NYSEAMERICAN:SYN) announced its quarterly earnings data on Wednesday, August, 8th. The company reported ($1.05) EPS for the quarter, topping analysts' consensus estimates of ($1.40) by $0.35. View Synthetic Biologics' Earnings History.
When is Synthetic Biologics' next earnings date?
What price target have analysts set for SYN?
2 analysts have issued 1 year price objectives for Synthetic Biologics' shares. Their forecasts range from $35.00 to $35.00. On average, they anticipate Synthetic Biologics' stock price to reach $35.00 in the next year. This suggests a possible upside of 1,172.7% from the stock's current price. View Analyst Price Targets for Synthetic Biologics.
What is the consensus analysts' recommendation for Synthetic Biologics?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synthetic Biologics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Synthetic Biologics.
What are Wall Street analysts saying about Synthetic Biologics stock?
Here are some recent quotes from research analysts about Synthetic Biologics stock:
- 1. According to Zacks Investment Research, "Synthetic Biologics, Inc. is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. The Company is engaged in developing product candidates to treat pulmonary arterial hypertension, relapses in multiple sclerosis, cognitive dysfunction in multiple sclerosis, fibromyalgia and amyotrophic lateral sclerosis. Synthetic Biologics, Inc., formerly known as Adeona Pharmaceuticals, Inc., is headquartered in Ann Arbor, Michigan. " (8/14/2018)
- 2. HC Wainwright analysts commented, "We base our $1 price target on probability-adjusted revenue forecasts for ribaxamase in the prevention of CDI and SYN-010 for the treatment of IBS-C. We use the net present value of our revenue forecast through 2028, apply a 35% probability of success (POS) for ribaxamase in CDI, a 25% POS for the early stage pipeline, and a 3x price/sales multiple to arrive at our $1 price target." (8/9/2018)
Are investors shorting Synthetic Biologics?
Synthetic Biologics saw a decline in short interest during the month of July. As of July 31st, there was short interest totalling 3,384,614 shares, a decline of 3.2% from the July 13th total of 3,496,969 shares. Based on an average trading volume of 446,180 shares, the days-to-cover ratio is currently 7.6 days. Approximately 2.9% of the shares of the stock are short sold. View Synthetic Biologics' Current Options Chain.
Who are some of Synthetic Biologics' key competitors?
Some companies that are related to Synthetic Biologics include ImmuPharma (IMM), Verona Pharma (VRP), Emblem (EMC), Cannabics Pharmaceuticals (CNBX), Oxford Biodynamics (OBD), Verseon (VSN), Silence Therapeutics (SLN), Trillium Therapeutics (TRIL), Tiziana Life Sciences (TILS), Bioventix (BVXP), Medicure Inc. Common Stock (MPH), Oncolytics Biotech (ONC), Kitrinor Metals (SCYB), Emblem (EMMBF) and Pfenex (PFNX).
Who are Synthetic Biologics' key executives?
Synthetic Biologics' management team includes the folowing people:
- Mr. Steven A. Shallcross, Interim CEO, CFO, Sec., Treasurer & Sec. (Age 57)
- Dr. Joseph A. Sliman, Chief Medical Officer (Age 45)
- Vincent I. Perrone, Director of Corp. Communication
- Dr. Michael Kaleko M.D., Ph.D., Sr. VP of R&D
- Dr. Raymond D. Stapleton Jr., Ph.D., Sr. VP of Manufacturing
Has Synthetic Biologics been receiving favorable news coverage?
Press coverage about SYN stock has trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Synthetic Biologics earned a news and rumor sentiment score of 0.16 on Accern's scale. They also gave media stories about the company an impact score of 46.55 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future. View Recent Headlines for Synthetic Biologics.
How do I buy shares of Synthetic Biologics?
Shares of SYN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Synthetic Biologics' stock price today?
One share of SYN stock can currently be purchased for approximately $2.75.
How big of a company is Synthetic Biologics?
Synthetic Biologics has a market capitalization of $49.23 million.
How can I contact Synthetic Biologics?
Synthetic Biologics' mailing address is 617 Detroit St Ste 100, ANN ARBOR, MI 48104-1125, United States. The company can be reached via phone at +1-734-3327800.
MarketBeat Community Rating for Synthetic Biologics (NYSEAMERICAN SYN)
MarketBeat's community ratings are surveys of what our community members think about Synthetic Biologics and other stocks. Vote "Outperform" if you believe SYN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYN will underperform the S&P 500 over the long term. You may vote once every thirty days.
